Evidence map›Paper›PMID 39534454›Full record

ReviewmHealth2024

Future challenges of direct-to-consumer genetic testing for sustainable safety in the Republic of Korea's skin care market: a systematic review.

Jinkyung Lee, Ki Han Kwon

Abstract readReview
In one paragraph

Review in mHealth, 2024. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 1 paper.

0numbers the graph read from it
0cells of the map it votes in
1citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

1 citing paper in PubMed.

  1. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

2 authors.

Jinkyung LeeDivision of Beauty Arts Care, Department of Practical Arts, Graduate School of Culture and Arts, Dongguk University, Seoul, Republic of Korea.ORCID https://orcid.org/0000-0003-3819-3066
Ki Han KwonCollege of General Education, Kookmin University, Seoul, Republic of Korea.

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

Background: Social distancing due to the pandemic is accelerating the fragmentation of Korean society in the megatrend of continuous individualization after industrialization. In this context, consumers are turning to direct-to-consumer (DTC) genetic testing for tailored skin healthcare strategies. However, there are still concerns about the safety of personal information in DTC genetic testing. The purpose of this review article is to examine the sustainable safety of DTC genetic testing for customized dermatology products, focusing on skin healthcare market after coronavirus disease 2019 (COVID-19). Methods: A systematic review approach was used in this study. Using the Preferred Reporting Items for Systematic Reviews and Meta-analyses (PRISMA) flow chart, a total of 920 references were selected from PubMed, Medline, and Scopus. The composition of a total of 59 references from professional papers was finally reviewed. To this end, the most relevant recent literature was added, and the reference period was limited to 2018 to 2023 based on a 6-year period. Results: With the practice of mask wearing since COVID-19, various methods are being used to strengthen the skin's immune system, and maintain and promote skin health. There is a need to have a method to increase the safety of DTC genetic testing for sustainable skin healthcare market. Conclusions: It is concluded that there is a need to continue to develop more sustainable and safer security applications (apps) in the field of customized dermatology cosmetics to address the privacy issues and improve the accuracy of DTC genetic testing.

Indexed as

Consumercustomized dermatological cosmeticsdirect-to-consumer genetic testing (DTC genetic testing)security applicationsustainable and safe

Identifiers

PMID39534454
PMCPMC11557158

What OpenQuestion holds

Textmetadata
LicenceCC BY-NC-ND
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.